PMID: 9169812Mar 15, 1997Paper

Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml

International Journal of Radiation Oncology, Biology, Physics
A V D'AmicoC N Coleman

Abstract

Biochemical failure-free survival stratified by the pretreatment prostate-specific antigen (PSA) and biopsy Gleason score (bGl) is determined for prostate cancer patients managed definitively with external beam radiation therapy or radical retropubic prostatectomy. A Cox regression multivariable analysis evaluating the variables of PSA, bGl, and clinical stage was used to evaluate the end point of time to PSA failure in 867 and 757 consecutive prostate cancer patients managed definitively with external beam radiation therapy or radical retropubic prostatectomy, respectively. PSA failure-free survival was determined using Kaplan-Meier analysis. Comparisons were made using the log rank test. The pretreatment PSA, bGl, and clinical stage (T3,4 vs. T1,T2) were found to be independent predictors of time to post-treatment PSA failure for both surgically and radiation managed patients using Cox regression multivariable analysis. Patients with a pretreatment PSA of > 4 ng/ml and < or = 20 ng/ml could be classified into risk groups for time to post-therapy PSA failure: low = PSA > 4-10 ng/ml and bGl < or = 4; intermediate = PSA > 4-10 and bGl 5-7; or PSA > 10-20 ng/ml and bGl < or = 7; high = PSA > 4-20 ng/ml and bGl > or = 8. Two-year ...Continue Reading

References

Aug 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A RitterT J Kinsella
Jan 1, 1986·The Prostate·M KuriyamaT Nishiura
May 1, 1988·International Journal of Radiation Oncology, Biology, Physics·G E Hanks
Sep 1, 1982·The Journal of Urology·D F PaulsonS Stephani
May 1, 1995·The Journal of Urology·K E RosenzweigR E Peschel
May 15, 1995·International Journal of Radiation Oncology, Biology, Physics·D A KubanP F Schellhammer
Aug 30, 1995·International Journal of Radiation Oncology, Biology, Physics·G K ZagarsA C von Eschenbach
Nov 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T M PisanskyJ E Oesterling
Jan 27, 1994·The New England Journal of Medicine·G W ChodakJ Warner
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G E HanksT E Schultheiss

❮ Previous
Next ❯

Citations

Mar 28, 2003·Lancet·Ashesh B Jani, Samuel Hellman
Jun 23, 2000·International Journal of Radiation Oncology, Biology, Physics·M ZaiderJ A Koutcher
Jul 4, 1998·International Journal of Radiation Oncology, Biology, Physics·M J ZelefskyZ Fuks
Jul 4, 1998·International Journal of Radiation Oncology, Biology, Physics·T P MateL Van Hollebeke
Mar 13, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D P Dearnaley
Dec 31, 2002·Urologic Oncology·Tony Y EngTerrence S Herman
Aug 31, 1999·International Journal of Urology : Official Journal of the Japanese Urological Association·K AkakuraH Ito
Nov 22, 2011·American Journal of Clinical Oncology·Brian J MoranGregory S Merrick
May 16, 2013·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Piyaporn BoonsirikamchaiHaesun Choi
Sep 17, 2013·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·R BoissierE Lechevallier
Apr 28, 2009·International Journal of Radiation Oncology, Biology, Physics·Giorgio ArcangeliMichele Gallucci
Jun 13, 2006·International Journal of Radiation Oncology, Biology, Physics·Orazio CaffoEnzo Galligioni
Oct 26, 2005·International Journal of Radiation Oncology, Biology, Physics·Julia J van Tol-GeerdinkWillem A J van Daal
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chaundre K CrossAnthony V D'Amico
Jul 22, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald C ChenJames A Talcott
Oct 6, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Ayal A AizerRichard E Peschel
Jul 8, 2011·The Cochrane Database of Systematic Reviews·Frank PeinemannStefan Sauerland
Feb 9, 2005·Prostate Cancer and Prostatic Diseases·W H HallS Vijayakumar

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.